|
|
残余胆固醇与血液透析患者血脂异常的现况
|
Abstract:
血液透析(HD)已成为大多数终末期肾病患者偏向选择的肾脏替代方式，心血管疾病(CVD)是其主要死亡原因。脂代谢紊乱是CVD和终末期肾病(ESRD)共同进展的机制。越来越多的证据表明，即使当低密度脂蛋白控制到最佳水平，残余胆固醇(RC)仍从流行病学及遗传学等方面被证明在预测ASCVD的发生中起着重要作用。现就HD患者血脂紊乱的特点及RC的定义、测量、机制、相关研究进展等进行总结。
Hemodialysis (HD) has become the preferred renal replacement for most patients with end-stage renal disease, and cardiovascular disease (CVD) is the leading cause of death. Dyslipidemia is a mechanism for the co-progression of CVD and end-stage renal disease (ESRD). There is increasing evidence that even when low-density lipoprotein is controlled to optimal levels, remnant cholester-ol (RC) is still proven to play an important role in predicting the occurrence of ASCVD from the as-pects of pathogenic mechanism, epidemiology and genetics. This article summarizes the character-istics of dyslipidemia in HD patients and the definition, measurement, mechanism, and related re-search progress of RC.
| [1] | Zhang, L.X., et al. (2012) Prevalence of Chronic Kidney Disease in China: A Cross-Sectional Survey. The Lancet, 379, 815-822. https://doi.org/10.1016/S0140-6736(12)60033-6 |
| [2] | Lu, R., Estremadoyro, C. and Chen, X. (2018) Hemodialysis versus Peritoneal Dialysis: An Observational Study in Two International Centers. The International Jour-nal of Artificial Organs, 41, 58-65.
https://doi.org/10.5301/ijao.5000656 |
| [3] | Vaziri, N.D. (2006) Dyslipidemia of Chronic Renal Failure: The Nature, Mechanisms, and Potential Consequences. American Journal of Physiology—Renal Physiology, 290, F262-F272. https://doi.org/10.1152/ajprenal.00099.2005 |
| [4] | Zoccali, C., Mallamaci, F. and Tripepi, G. (2004) Novel Cardio-vascular Risk Factors in End-Stage Renal Disease. Journal of the American Society of Nephrology, 15, S77-S80. https://doi.org/10.1097/01.ASN.0000093240.84097.FE |
| [5] | Baigent, C., et al. (2011) The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease (Study of Heart and Renal Protection): A Randomised Placebo-Controlled Trial. The Lancet, 377, 2181-2192. |
| [6] | 康伟平. 阿托伐他汀对高脂血症合并慢性肾脏病患者心血管风险影响的临床研究[J]. 中国现代药物应用, 2019, 13(1): 125-126. |
| [7] | Hou, W.Y., et al. (2013) Effect of Statin Therapy on Cardiovascular and Renal Outcomes in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. European Heart Journal, 34, 1807-1817.
https://doi.org/10.1093/eurheartj/eht065 |
| [8] | Messow, C.M. and Isles, C. (2017) Meta-Analysis of Statins in Chronic Kidney Disease: Who Benefits? QJM, 110, 493-500. https://doi.org/10.1093/qjmed/hcx040 |
| [9] | Wanner, C., et al. (2005) Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. The New England Journal of Medicine, 353, 238-248. https://doi.org/10.1056/NEJMoa043545 |
| [10] | Fellstr？m, B.C., et al. (2009) Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. The New England Journal of Medicine, 360, 1395-1407. https://doi.org/10.1056/NEJMoa0810177 |
| [11] | Sandesara, P.B., Virani, S.S., Fazio, S., et al. (2019) The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. En-docrine Reviews, 40, 537-557. https://doi.org/10.1210/er.2018-00184 |
| [12] | Nordestgaard, B.G. (2016) Triglycer-ide-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights from Epidemiology, Genetics, and Bi-ology. Circulation Research, 118, 547-563.
https://doi.org/10.1161/CIRCRESAHA.115.306249 |
| [13] | Varbo, A., Freiberg, J.J. and Nordestgaard, B.G. (2015) Extreme Nonfasting Remnant Cholesterol vs Extreme LDL Cholesterol as Contributors to Cardiovascular Disease and All-Cause Mortality in 90000 Individuals from the General Population. Clinical Chemistry, 61, 533-543. https://doi.org/10.1373/clinchem.2014.234146 |
| [14] | Bruemmer, D. and Cho, L. (2021) Remnant Cholesterol. Cir-culation: Cardiovascular Imaging, 14, e12615.
https://doi.org/10.1161/CIRCIMAGING.121.012615 |
| [15] | Qian, S., You, S. and Sun, Y. (2021) Remnant Choles-terol and Common Carotid Artery Intima-Media Thickness in Patients with Ischemic Stroke. Circulation: Cardiovascular Imaging, 14, e010953.
https://doi.org/10.1161/CIRCIMAGING.120.010953 |
| [16] | Casta？er, O., Pintó, X. and Subirana, I. (2020) Remnant Cholesterol, Not LDL Cholesterol, Is Associated with Incident Cardiovascular Disease. Journal of the American College of Cardiology, 76, 2712-2724.
https://doi.org/10.1016/j.jacc.2020.10.008 |
| [17] | Bernelot Moens, S.J., Verweij, S.L. and Schnitzler, J.G. (2017) Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans. Arterio-sclerosis, Thrombosis, and Vascular Biology, 37, 969-975. https://doi.org/10.1161/ATVBAHA.116.308834 |
| [18] | Wadstr？m, B.N., Wulff, A.B., Pedersen, K.M., et al. (2021) Elevated Remnant Cholesterol Increases the Risk of Peripheral Artery Disease, Myocardial Infarction, and Ischaemic Stroke: A Cohort-Based Study. European Heart Journal, ehab705. https://doi.org/10.1093/eurheartj/ehab705 |
| [19] | Xu, J., Qu, P. and Du, X. (2021) Change in Postprandial Level of Remnant Cholesterol after a Daily Breakfast in Chinese Patients with Hypertension. Frontiers in Cardiovascular Medi-cine, 8, Article ID: 685385.
https://doi.org/10.3389/fcvm.2021.685385 |
| [20] | Varbo, A. and Nordestgaard, B.G. (2021) Directly Measured vs. Calculated Remnant Cholesterol Identifies Additional Overlooked Individuals in the General Population at Higher Risk of Myocardial Infarction. European Heart Journal, 42, 4833-4843. https://doi.org/10.1093/eurheartj/ehab293 |
| [21] | 聂大奥, 林桥文, 谭文惠, 等. 残余胆固醇水平对急性脑梗死发病的预测价值[J]. 实用医学杂志, 2021, 37(13): 1711-1713. |
| [22] | Jansson, S.F., Dahlstr？m, E.H., Forsblom, C., et al. (2021) Remnant Cholesterol Predicts Progression of Diabetic Nephropathy and Retinopathy in Type 1 Diabetes. Journal of Internal Medicine, 290, 632-645.
https://doi.org/10.1111/joim.13298 |
| [23] | Cao, Y., Zhang, H. and Jin, J. (2020) The Longitudinal Association of Remnant Cholesterol with Cardiovascular Outcomes in Patients with Diabetes and Pre-Diabetes. Cardiovascular Dia-betology, 19, 104.
https://doi.org/10.1186/s12933-020-01076-7 |
| [24] | Zhang, S., Cheng, S. and He, X. (2022) Remnant Lipoprotein Cholesterol as a Factor Related to Adult Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism, 107, e1598-e1609.
https://doi.org/10.1210/clinem/dgab825 |
| [25] | Zou, Y., Hu, C., Kuang, M., et al. (2022) Remnant Cholester-ol/High-Density Lipoprotein Cholesterol Ratio Is a New Powerful Tool for Identifying Non-Alcoholic Fatty Liver Dis-ease. BMC Gastroenterology, 22, Article No. 134.
https://doi.org/10.1186/s12876-022-02216-x |
| [26] | Tsimihodimos, V., Mitrogianni, Z. and Elisaf, M. (2011) Dyslipidemia Associated with Chronic Kidney Disease. The Open Cardiovascular Medicine Journal, 5, 41-48. https://doi.org/10.2174/1874192401105010041 |
| [27] | Vaziri, N.D. (2018) Molecular Mechanisms of Disorders of Lipid Metabolism in Chronic Kidney Disease. Frontiers in Bioscience, 23, 146-161. https://doi.org/10.2741/4585 |
| [28] | Shapiro, M.D. and Fazio, S. (2016) From Lipids to Inflammation. Circulation Research, 118, 732-749.
https://doi.org/10.1161/CIRCRESAHA.115.306471 |
| [29] | Nosratola, D. and Vaziri, H.M. (2006) Mechanisms of Dyslipidemia of Chronic Renal Failure. Hemodialysis International, 10, 1-7. https://doi.org/10.1111/j.1542-4758.2006.01168.x |
| [30] | Chan, M.K., et al. (1984) Pathogenic Roles of Post-Heparin Lipases in Lipid Abnormalities in Hemodialysis Patients. Kidney International, 25, 812-818. https://doi.org/10.1038/ki.1984.94 |
| [31] | Kim, C. and Vaziri, N.D. (2005) Down-Regulation of Hepatic LDL Re-ceptor-Related Protein (LRP) in Chronic Renal Failure. Kidney International, 67, 1028-1032. https://doi.org/10.1111/j.1523-1755.2005.00166.x |
| [32] | Chang, T.I., et al. (2017) Association of Serum Tri-glyc-Eride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clinical Journal of the American Society of Nephrology, 12, 591- 602. https://doi.org/10.2215/CJN.08730816 |
| [33] | Homma, K., et al. (2013) Skew of Plasma Low- and High-Density Lipoprotein Distributions to Less Dense Subfractions in Normotriglyceridemic Chronic Kidney Disease Patients on Maintenance Hemodialysis Treatment. Nephron Clinical Practice, 123, 41-45. https://doi.org/10.1159/000351506 |
| [34] | Calabresi, L., et al. (2015) Acquired Lecithin: Cholesterol Acyltransferase Deficiency as a Major Factor in Lowering Plasma HDL Levels in Chronic Kidney Disease. Journal of Internal Medicine, 5, 552-561.
https://doi.org/10.1111/joim.12290 |
| [35] | Vaziri, N.D. (2016) HDL Abnormalities in Nephrotic Syndrome and Chronic Kidney Disease. Nature Reviews Nephrology, 12, 37-47. https://doi.org/10.1038/nrneph.2015.180 |
| [36] | Chang, T.I., et al. (2018) Increments in Serum High-Density Lipo-protein Cholesterol over Time Are Not Associated with Improved Outcomes in Incident Hemodialysis Patients. Journal of Clinical Lipidology, 12, 488-497.
https://doi.org/10.1016/j.jacl.2018.01.010 |
| [37] | Bowe, B., Xie, Y., Xian, H., et al. (2016) High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans. Clinical Journal of the American Society of Nephrology, 11, 1784-1793.
https://doi.org/10.2215/CJN.00730116 |
| [38] | Kronenberg, F. (2018) High-Density Lipoprotein in Chronic Kidney Diseases—The Devil Is in the Detail. Journal of the American Society of Nephrology, 29, 1356-1371. https://doi.org/10.1681/ASN.2017070798 |
| [39] | Chapman, M.J., et al. (2011) Triglyceride-Rich Lipoproteins and High-Density Lipoprotein Cholesterol in Patients at High Risk of Cardiovascular Disease: Evidence and Guidance for Management. European Heart Journal, 32, 1345- 1361. https://doi.org/10.1093/eurheartj/ehr112 |
| [40] | Martin, S.S., Blaha, M.J., Elshazly, M.B., et al. (2013) Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels from the Standard Lipid Profile. JAMA, 310, 2061-2068.
https://doi.org/10.1001/jama.2013.280532 |
| [41] | Chen, J., Kuang, J. and Tang, X. (2020) Comparison of Calculated Remnant Lipoprotein Cholesterol Levels with Levels Directly Measured by Nuclear Magnetic Resonance. Lipids in Health and Disease, 19, Article No. 132.
https://doi.org/10.1186/s12944-020-01311-w |
| [42] | Quispe, R., Martin, S.S. and Michos, E.D. (2021) Remnant Cholesterol Predicts Cardiovascular Disease beyond LDL and ApoB: A Primary Prevention Study. European Heart Journal, 42, 4324-4332.
https://doi.org/10.1093/eurheartj/ehab432 |
| [43] | Nakajima, K., et al. (2006) The Oxidative Modification Hypothesis of Atherosclerosis: The Comparison of Atherogenic Effects on Oxidized LDL and Remnant Lipoproteins in Plasma. Clinica Chimica Acta, 367, 36-47.
https://doi.org/10.1016/j.cca.2005.12.013 |
| [44] | Carvalho, L.S.F., Bense？or, I.M. and Nogueira, A.C.C. (2021) In-creased Particle Size of Triacylglycerol-Enriched Remnant Lipoproteins, But Not Their Plasma Concentration or Lipid Content, Augments Risk Prediction of Incident Type 2 Diabetes. Diabetologia, 64, 385-396. https://doi.org/10.1007/s00125-020-05322-1 |
| [45] | Varbo, A., et al. (2013) Elevated Remnant Cholesterol Causes both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease without Inflammation. Circulation, 128, 1298-1309. https://doi.org/10.1161/CIRCULATIONAHA.113.003008 |
| [46] | Horace, R.W., et al. (2022) Remnant Cholesterol Is Prospectively Associated with Cardiovascular Disease Events and All-Cause Mortality in Kidney Transplant Recipi-ents: The FAVORIT Study. Nephrology Dialysis Transplantation, 37, 382-389. https://doi.org/10.1093/ndt/gfab068 |
| [47] | Yan, P., Xu, Y. and Miao, Y. (2021) Association of Remnant Cholesterol with Chronic Kidney Disease in Middle- Aged and Elderly Chinese: A Population-Based Study. Acta Diabetologica, 58, 1615-1625.
https://doi.org/10.1007/s00592-021-01765-z |
| [48] | Zhai, Q., Dou, J., Wen, J., et al. (2022) Association between Changes in Lipid Indexes and Early Progression of Kidney Dysfunction in Participants with Normal Estimated Glomeru-lar Filtration Rate: A Prospective Cohort Study. Endocrine, 76, 312-323. https://doi.org/10.1007/s12020-022-03012-z |
| [49] | Szili-Torok, T., Sokooti, S., Osté, M., et al. (2022) Remnant Lipoprotein Cholesterol Is Associated with Incident New Onset Diabetes after Transplantation (NODAT) in Renal Transplant Recipients: Results of the Transplant Lines Biobank and Cohort Studies. Cardiovascular Diabetology, 21, 41. https://doi.org/10.1186/s12933-022-01475-y |
| [50] | Xu, Y., Yang, G., Zuo, X., et al. (2022) A Systematic Review for the Efficacy of Coenzyme Q10 in Patients with Chronic Kidney Disease. International Urology and Nephrology, 54, 173-184. https://doi.org/10.1007/s11255-021-02838-2 |
| [51] | George, M., et al. (2015) Looking into the Crystal Ball-Upcoming Drugs for Dyslipidemia. Journal of Cardiovascular Pharmacology and Therapeutics, 20, 11-20. https://doi.org/10.1177/1074248414545127 |
| [52] | Chapman, M.J., Zamorano, J.L. and Parhofer, K.G. (2022) Re-ducing Residual Cardiovascular Risk in Europe: Therapeutic Implications of European Medicines Agency Approval of Icosapent Ethyl/Eicosapentaenoic Acid. Pharmacology & Therapeutics, 237, Article ID: 108172. https://doi.org/10.1016/j.pharmthera.2022.108172 |
